Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
NXT2B AB, founded in 2011 by Swedish entrepreneur Bengt Ågerup, is a privately owned venture capital firm based in Uppsala, Sweden. The firm focuses on growth equity investments primarily in the healthcare, medical devices, and specialty pharmaceuticals sectors. NXT2B has invested in over 30 companies since its inception, emphasizing a rapid decision-making process due to its private ownership structure.
The firm operates with a commitment to supporting early-phase projects that exhibit high scientific quality and viable business opportunities. NXT2B's investment strategy is characterized by long-term active ownership, allowing it to provide significant value to its portfolio companies. The firm has established itself as a key player in the Nordic life sciences ecosystem, leveraging its deep commercialization experience to help management teams navigate the complexities of building market-leading companies.
As of now, NXT2B has a diverse portfolio that includes notable companies in the healthcare and biotech sectors. The firm’s approach is particularly appealing to founders seeking patient capital and strategic support in the life sciences domain.
NXT2B specializes in growth equity investments across several sectors, including healthcare, medical devices, specialty pharmaceuticals, technology, and consumer products. The firm is particularly interested in early-phase projects that demonstrate high scientific quality and reasonable business opportunities. NXT2B's investment strategy emphasizes long-term active ownership, which allows the firm to engage deeply with its portfolio companies.
The firm primarily targets investments within Europe, with a strong focus on the Nordic region. NXT2B seeks to partner with companies that have defensible scientific foundations and innovative business models. The firm values management teams that are open to collaboration and are looking for an active partner to help navigate the complexities of growth in the healthcare and biotech sectors.
Check sizes are not publicly disclosed, but NXT2B has participated in significant funding rounds, including a SEK 90 million Series A for Navinci Diagnostics in 2022. The firm’s hands-on approach and commitment to scientific rigor make it a compelling choice for founders in the life sciences space.
NXT2B's portfolio includes over 30 companies, with a strong emphasis on healthcare and biotech. Notable portfolio companies include:
This diverse portfolio reflects NXT2B's commitment to investing in high-quality scientific projects that have the potential to lead the market.
Erika Kjellberg Eriksson - CEO and Chair of the Board. Erika has over 20 years of experience in life sciences, previously serving as CFO of OxThera and Vice President and CFO of Q-Med. She holds a strong background in financial management and strategic planning.
Bengt Ågerup - Founder and Senior Adviser. Bengt founded NXT2B in 2011 and has held senior positions at Pharmacia and Biomatrix. He is known for founding Q-Med, which was sold to Galderma in 2011. His expertise lies in strategic investment and life sciences.
Per-Olof Wallström - Board Member. Per-Olof has 50 years of experience in the pharmaceutical and biotech industries, having held senior roles at Merck, Astra, and Bristol-Myers Squibb. He has also served as CEO at Karo Bio and Melacure Therapeutics.
Angelica Loskog - Scientific Adviser. Angelica is the CEO of Lokon Pharma and a professor of immunotherapy at Uppsala University. Her focus is on immune, gene, and cell therapy for cancer and autoimmune diseases, bringing significant scientific expertise to the team.
To pitch NXT2B, founders should send an email to info@nxt2b.com. It is essential to include a comprehensive pitch deck that outlines the startup's vision, scientific foundation, and market opportunity. NXT2B appreciates clarity and detail in presentations.
While specific response time expectations are not disclosed, founders should anticipate a thorough review process given the firm's commitment to high-quality investments. Warm introductions are beneficial but not strictly necessary.
In July 2022, NXT2B participated in a SEK 90 million Series A funding round for Navinci Diagnostics AB, a life-science tools company. This investment highlights NXT2B's commitment to supporting innovative healthcare solutions.
In 2011, NXT2B made its first major investment by acquiring 49% of Olink AB, a company focused on advancing proteomics technology. This investment was pivotal in supporting Olink's commercialization and growth.
Recent activity signals include a reported pre-seed round involving Innocens in November 2025, indicating NXT2B's ongoing engagement in the life sciences sector.
What are NXT2B's investment criteria?
NXT2B focuses on growth equity investments in sectors such as healthcare, medical devices, specialty pharmaceuticals, technology, and consumer products. The firm seeks early-phase projects that demonstrate high scientific quality and viable business opportunities.
How can founders pitch to NXT2B?
Founders can reach out to NXT2B via email at info@nxt2b.com. It is advisable to include a detailed pitch deck that outlines the business model, scientific foundation, and market potential.
What makes NXT2B different from other venture capital firms?
NXT2B is privately owned, allowing for faster decision-making without the need for external capital approval. This structure enables the firm to engage deeply with its portfolio companies and provide long-term active ownership.
What is NXT2B's geographic focus?
The firm primarily invests in Europe, with a strong emphasis on the Nordic region, particularly Sweden. NXT2B is well-integrated into the local life sciences ecosystem.
What is NXT2B's post-investment involvement like?
NXT2B provides active support to its portfolio companies, leveraging its deep commercialization experience to help management teams navigate growth challenges and build market-leading companies.
What is the typical check size for NXT2B?
While specific check sizes are not disclosed, NXT2B has participated in significant funding rounds, indicating a capacity for substantial investments in promising companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.